On this episode of Stock Movers:
- Novo Nordisk pared its forecast for a fourth time this year on lagging sales of its blockbuster drugs Wegovy and Ozempic, underscoring the urgency facing its new CEO.
- Orsted has confirmed its full-year profit guidance, seeking to reassure investors of its financial stability after a weak third quarter..
- M&S expects profit in the second half to rebound to at least last year’s level as the British retailer tries to move on from a costly cyberattack.

On this episode of Stock Movers: - Novo Nordisk pared its forecast for a fourth time this year on lagging sales of its blockbuster drugs Wegovy and Ozempic, underscoring the urgency facing its new CEO. - Orsted has confirmed its full-year profit guidance, seeking to reassure investors of its financial stability after a weak third quarter.. - M&amp;S expects profit in the second half to rebound to at least last year&rsquo;s level as the British retailer tries to move on from a costly cyberattack.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Novo Up, Orsted Gains, M&S Dips

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/b0cfcc59-740d-4771-9a86-b38c00aaf6da/transcript

Advertisement